boemel schreef op 7 oktober 2012 23:25:
[...]
www.pharming.com/index.php?act=show&a...Closed a commercialization agreement with Santarus (SNTS) for the commercialization of Rhucin® in North America and received a US$15.0 million upfront payment
Under this agreement with Santarus, an additional US$30 million" MAY POTENTIALLY" become payable based on achieving certain clinical and commercial milestones and US$5 million for the acceptance of the BLA for review by the FDA
Under the same agreement, a further US$45 million "MAY BE" received upon reaching certain levels of aggregate net sales levels of Rhucin. The amount of each such sales based milestone payment varies upon the level of net sales in a calendar year. The maximum amount of all such milestone payments to Pharming would be US$45 million, assuming net sales exceeded US$500 million in a calendar year
Submitted the BLA to the US FDA
heb mijn boodschap hier in hoofdletters geplaatst ,weet niet hoe ik ze vet moet plaatsen, jaja, ik ben een dummy:-)
www.pharming.com/index.php?act=show&a...